Emblaveo (aztreonam/avibactam) / Pfizer, AstraZeneca, AbbVie - LARVOL DELTA

4990 - Emerging resistance to new antibiotics: are we already losing the newest tools? (ESCMID Global 2026) - "This session explores the troubling rise of resistance to recently approved antibiotics, including cefiderocol, ceftazidime-avibactam, imipenem/relebactam, cefepime-taniborbactam, aztreonam-avibactam, etc. Although these drugs were introduced as critical last-resort options against multidrug-resistant infections, reports of resistance have emerged within just a few years of clinical use. The panel will address the urgent need for improved stewardship, faster diagnostics, and equitable access to new antibiotics to preserve their effectiveness. Participants will gain insights into how resistance spreads, how policies impact antimicrobial use, and what strategies might still help us stay ahead in the race against resistant pathogens."

Infectious Disease

Activity of novel antibiotics against dual metallo-Beta-lactamase producing Enterobacter hormaechei clinical isolates. (PubMed, JAC Antimicrob Resist) - "Our findings indicate that E. hormaechei clinical isolates co-producing NDM and VIM metallo-carbapenemases exhibited susceptibility to all tested novel BL/BLIs, including aztreonam/avibactam, cefepime/taniborbactam and cefepime/zidebactam. The combination of cefiderocol and xeruborbactam restored the activity of cefiderocol."

Journal • Infectious Disease

Development of a rapid susceptibility testing system for cefiderocol, aztreonam/avibactam, ceftolozane/tazobactam and meropenem/vaborbactam directly from positive blood cultures (ESCMID Global 2026) - No abstract available

Activity of aztreonam/avibactam, cefiderocol and cefiderocol-containing combinations against Stenotrophomonas maltophilia from Greece (ESCMID Global 2026) - No abstract available

Activity of cefiderocol/xeruborbactam against NDM-producing Escherichia coli isolates with PBP3 insertions and decreased susceptibility or resistance to aztreonam/avibactam, cefiderocol, and cefepime/taniborbactam (ESCMID Global 2026) - No abstract available

NDM Escherichia coli with aztreonam/avibactam and/or cefiderocol resistance in immunocompromised paediatric patients and use of cefepime/zidebactam (ESCMID Global 2026) - No abstract available

Clinical • Pediatrics

New EUCAST RAST breakpoints for Escherichia coli and Klebsiella pneumoniae with aztreonam/avibactam and cefiderocol (ESCMID Global 2026) - No abstract available

Infectious Disease • Pneumonia

The in vitro activity of aztreonam/avibactam and cefiderocol against Escherichia coli isolates that carry insertions in penicillin-binding protein 3 (PBP3) with and without acquired AmpC as a part of the ATLAS global surveillance program, 2024 (ESCMID Global 2026) - No abstract available

Preclinical

Ceftazidime/avibactam and aztreonam combined with an aminoglycoside combat metallo-β-lactamase-producing Klebsiella pneumoniae. (PubMed, Antimicrob Agents Chemother) - "Combination regimens with aminoglycosides (amikacin or plazomicin) occasionally demonstrated synergy using traditional definitions based on viable colony counting, but they were able to consistently reduce bacterial turbidity and the emergence of filamentous cells that were observed during exposure to ceftazidime/avibactam + aztreonam. Combinations between ceftazidime/avibactam, aztreonam, and an aminoglycoside are a potentially promising therapeutic strategy to combat the rising threat posed by MBL-producing K. pneumoniae."

Journal • Infectious Disease • Pneumonia

Successful treatment of sequential pulmonary and bloodstream infections caused by Stenotrophomonas maltophilia with aztreonam/avibactam: a case report (ESCMID Global 2026) - No abstract available

Case report • Clinical • Infectious Disease

When in vitro meets in vivo: therapeutic role of ceftazidime/avibactam & aztreonam in metallo-β-lactamase-producing, colistin-resistant Klebsiella pneumoniae and Pseudomonas aeruginosa: a five-case translational experience (ESCMID Global 2026) - No abstract available

Preclinical • Infectious Disease • Pneumonia

Case report: treatment of intracranial CRE Klebsiella pneumoniae infection following surgery of intracerebral haemorrhage with aztreonam/avibactam (ESCMID Global 2026) - No abstract available

Case report • Clinical • Surgery • Infectious Disease • Pneumonia

?Aztreonam/avibactam as treatment for VIM-producing carbapenem-resistant Klebsiella pneumoniae complicated urinary tract infection in an elderly patient: a case report (ESCMID Global 2026) - No abstract available

Case report • Clinical • Infectious Disease • Nephrology • Pneumonia

Case Report: aztreonam-avibactam for bloodstream infection caused by metallo-β-lactamase-producing carbapenem-resistant Klebsiella pneumoniae after allogeneic haematopoietic stem cell transplantation (ESCMID Global 2026) - No abstract available

Case report • Clinical • Infectious Disease • Pneumonia • Transplantation

Precision dosing and therapeutic drug monitoring of aztreonam/avibactam in a liver transplant recipient with CRKP infection and acute kidney injury (ESCMID Global 2026) - No abstract available

Clinical • Acute Kidney Injury • Infectious Disease • Nephrology • Renal Disease • Transplantation

Rapid microbiological and genomic clearance of MBL-CRE pneumonia following tNGS-guided aztreonam/avibactam therapy in a 93-year-old patient (ESCMID Global 2026) - No abstract available

Clinical • Infectious Disease • Pneumonia • Respiratory Diseases

In vitro activity of aztreonam/avibactam and distribution of carbapenemase genes in ceftazidime/avibactam-resistant carbapenem-resistant Enterobacterales: data from the global antimicrobial testing leadership and surveillance, 2019–2023 (ESCMID Global 2026) - No abstract available

Preclinical

In vitro activity of aztreonam/avibactam against metallo-β-lactamase-producing Enterobacterales isolated from urine samples (ESCMID Global 2026) - No abstract available

Preclinical

The in vitro activity of aztreonam/nacubactam and cefepime/nacubactam against molecularly characterised Enterobacterales isolates including those with ceftazidime-avibactam and aztreonam/avibactam resistance mechanisms collected globally from 2021-2023 (ESCMID Global 2026) - No abstract available

Preclinical

Broad-spectrum in vitro activity of ceftazidime/avibactam/aztreonam against Klebsiella pneumoniae with diverse resistance mechanisms (ESCMID Global 2026) - No abstract available

Preclinical • Infectious Disease • Pneumonia

Aztreonam-avibactam for infections caused by metallo-β-lactamase-producing Enterobacterales (ESCMID Global 2026) - No abstract available

Infectious Disease

The in vitro activity of aztreonam/avibactam and comparator agents against isolates of hypervirulent Klebsiella pneumoniae with carbapenemases and ESBLs collected as a part of the ATLAS global surveillance program, 2024 (ESCMID Global 2026) - No abstract available

Preclinical • Infectious Disease • Pneumonia

In vitro activity of aztreonam/avibactam against VIM-producing Pseudomonas aeruginosa in Germany (ESCMID Global 2026) - No abstract available

Preclinical

Comparison of agar diffusion and gradient test for determining susceptibility to aztreonam/avibactam (ESCMID Global 2026) - No abstract available

In vitro activity of aztreonam/avibactam against carbapenem-resistant Enterobacterales isolates from the ATLAS India data (2024) (ESCMID Global 2026) - No abstract available

Preclinical